Mitogen-activated protein kinase kinase kinase 7 (TAK1) (MAP3K7)

Mitogen-activated protein kinase kinase kinase 7 (TAK1) is a critical serine/threonine kinase that serves as a central hub in the signaling cascades of the interleukin-1 receptor (IL-1R), tumor necrosis factor receptor (TNFR), and Toll-like receptors (TLRs) [1, 5]. Upon activation, TAK1 forms a complex with its regulatory subunits, TAB1 and TAB2 or TAB3, which then activates two major downstream pathways: the nuclear factor-kappa B (NF-κB) pathway via the IKK complex and the mitogen-activated protein kinase (MAPK) pathways involving p38 and JNK [3, 5]. These pathways are essential for the production of pro-inflammatory cytokines and the regulation of cell survival, differentiation, and apoptosis [1, 3]. In many inflammatory diseases and cancers, TAK1 signaling is dysregulated, promoting chronic inflammation or tumor cell resistance to apoptosis [4]. Consequently, TAK1 is a high-interest therapeutic target, with small-molecule inhibitors like Takinib being developed to treat autoimmune disorders and various malignancies [2]. However, because TAK1 is vital for maintaining the integrity of certain tissues like the liver and gut, therapeutic strategies must carefully balance efficacy with potential toxicity [5]. The development of selective inhibitors aims to target specific disease states while minimizing these systemic safety concerns [2, 3].

Other names

TAK1Transforming growth factor-beta-activated kinase 1MAP3K7MEKK7TGF-beta-activated kinase 1

Inhibition of the kinase activity of MAP3K7 (TAK1), which prevents the phosphorylation and activation of downstream MAP kinase kinases (MKK3/6 and MKK4/7) and the IKK complex, thereby suppressing the p38, JNK, and NF-kappaB signaling pathways.